Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AMGEN INC Director's Dealing 2024

Nov 7, 2024

29819_dirs_2024-11-06_8f4fbb4b-f7bd-443e-a10b-13a99db75aa9.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2024-11-05

Reporting Person: Busch Matthew C. (VP, Finance & CAO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-11-05 Common Stock F 189 $316.91 Disposed 4770 Direct

Footnotes

F1: These shares include the following Restricted Stock Units (RSUs) granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Plan): 43 RSUs which will vest on 4/30/2025; 509 RSUs which will vest on 11/5/2025; 144 RSUs which will vest in installments of 71 on 5/2/2025, and 73 on 5/2/2026; 296 RSUs which will vest in installments of 97 on 5/2/2025, 98 on 5/2/2026 and 101 on 5/2/2027; and 333 RSUs which will vest in installments of 109 on 5/7/2026, 110 on 5/7/2027, and 114 on 5/7/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2: These shares include 90 Dividend Equivalents (DEs) granted pursuant to the Company's Equity Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.